Neuroimmunology
Autoantibodies: mechanism and testing
Dec. 20, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Anti-NMDA receptor encephalitis …
- Updated 08.07.2024
- Released 09.02.2018
- Expires For CME 08.07.2027
Anti-NMDA receptor encephalitis
Introduction
Overview
Anti-NMDA receptor encephalitis is an autoimmune disorder that affects people of all ages, but predominantly young women (about 50% with an associated ovarian teratoma) and children of both sexes. Patients present with neuropsychiatric manifestations and memory and cognitive deficits and usually progress to catatonia, seizures, autonomic dysfunction, stereotypic movements, and coma. Recovery can be prolonged. The diagnosis can be strongly suspected by history and clinical evaluation and confirmed by detection of CSF IgG antibodies to the GluN1 subunit of the NMDA receptor. Patients often respond to a combination of immunotherapy, including corticosteroids, IVIg or plasma exchange, rituximab, or cyclophosphamide.
Key points
|
• Anti-NMDA receptor encephalitis is mediated by specific IgG autoantibodies to the GluN1 subunit of the NMDA receptor. | |
|
• Most patients present with neuropsychiatric symptoms that progress to include seizures, movement disorders, autonomic dysfunction, sleep disturbances, and decreased level of consciousness. | |
|
• The underlying mechanism of the disorder is a reversible antibody-mediated reduction of synaptic NMDA receptors. | |
|
• Almost 80% of patients have full or substantial recovery with early initiation of immunotherapy, and removal of an associated tumor, if present (usually ovarian teratoma), is associated with better outcomes. |
Historical note and terminology
In 2005, four young women with ovarian teratoma and subacute psychiatric symptoms, seizures, decreased level of consciousness, and frequent central hypoventilation of unknown etiology were reported (48). The patients had inflammatory abnormalities in the cerebrospinal fluid, and all improved after tumor resection, immunotherapy, or both. This supported a paraneoplastic etiology, but some of the teratomas were benign and none of the patients had paraneoplastic (onconeural) antibodies, which target intracellular neuronal antigens. Rather, all had an immune response targeting an antigen enriched in the neuropil of the hippocampus that was subsequently identified to be the N-methyl-D-aspartate (NMDA) receptor (16). The response to immunotherapy and the location and function of the NMDA receptor suggested that the disorder, now called anti-NMDA receptor encephalitis, was mediated by the antibodies. Using the presence of the antibodies as a diagnostic test, it soon became clear that this disorder occurs with and without a tumor association and can occur in men (13). It was also shown that similar previously reported cases (some grouped under the term “acute nonherpetic encephalitis of juvenile onset”) were, in fact, cases of anti-NMDA receptor encephalitis. The characterization of anti-NMDA receptor encephalitis led to the identification of other encephalitic syndromes, each associated with a specific pathogenic autoantibody that targets neuronal receptors, channels, or synaptic proteins (14). This group of disorders is now often referred to as “antibody-mediated encephalitis” or “autoimmune encephalitis.”
Clinical manifestations
Presentation and course
NMDA receptor encephalitis primarily affects young women (median age 21 years) who represent about 80% of cases; 40% of the patients are younger than 18 years of age, with babies as young as 2 months old (47). There is an age-related relationship with the presence of a teratoma. Almost 50% of female patients older than 12 years of age have uni- or bilateral ovarian teratomas compared with only 8% of younger girls. About 5% of male patients have tumors, most often a testicular germ cell tumor. Rare associations with other tumors (small cell lung cancer, breast cancer, Hodgkin lymphoma, among others), frequently affecting patients older than 45 years of age, have been reported (15).
Most patients present with acute changes in behavior and personality, with memory loss that worsens over a few days or weeks and can manifest as anxiety, paranoia, delusions, hallucinations, pressured speech, manic or aggressive behavior, and alternating episodes of extreme agitation and catatonia. In retrospect, almost 70% of patients report a viral-like prodrome with headache or fever. Almost all patients have insomnia, but this can be missed if not specifically addressed when obtaining the medical history (02). In some patients, the insomnia can predate by weeks the onset of other symptoms. In children under 12 years of age, initial manifestations are more commonly behavioral changes (irritability, agitation), insomnia, movement disorders, seizures, and decreased verbal output (06). Despite this age-related difference in initial presentation, within a few weeks of onset, patients evolve to a similar spectrum of symptoms that include the development of abnormal movements (often oral-facial or limb dyskinesias, choreoathetosis, dystonic postures), seizures, autonomic instability (eg, central hypoventilation, tachycardia, hyperthermia, hypertension, and less frequently bradycardia or cardiac pauses), and decline in the level of consciousness to a comatose state. Atypical symptoms such as cerebellar ataxia or hemiparesis are rare and more commonly seen in children. Isolated psychiatric episodes have been reported, but most of these patients have subtle neurologic findings or abnormalities on ancillary testing such as CSF pleocytosis or brain MRI findings (33). Recovery from the acute stage is usually in inverse order of symptom development with initial resolution of seizures, abnormal movements, autonomic dysfunction, and insomnia being replaced by hypersomnia (02). At this point, patients enter a postacute stage characterized by a cognitive-psychiatric syndrome and residual, usually mild neurologic deficits from the acute stage (27). During this time, patients often have adjustment difficulties that should not be ignored. Full recovery of memory, attention, and normal sleep and behavior is slow and can take months.
Proposed diagnostic criteria for probable anti-NMDA receptor encephalitis requires the presence of (1) the rapid onset of at least four of the following symptom groups: abnormal behavior or cognitive dysfunction, speech dysfunction, seizures, movement disorder, decreased level of consciousness, autonomic dysfunction, or hypoventilation (or three of these plus ovarian teratoma); (2) abnormal EEG or CSF pleocytosis or oligoclonal bands; and (3) reasonable exclusion of other disorders (23). A definite diagnosis can be made in the presence of one or more of the symptom groups in point 1 and the detection of IgG anti-NMDA receptor antibodies, after reasonable exclusion of other disorders. Testing CSF is preferable as studies have shown that about 13% of patients with positive CSF can have negative serum studies (24; 26).
Prognosis and complications
The prognosis of anti-NMDA receptor encephalitis is good, and about 80% of patients have substantial or full recovery by 24 months (modified Rankin scale scores 0-2) (47). Independent predictors for good outcome are lack of need for intensive care, early initiation of immunotherapy (within 4 weeks of presentation), clinical improvement within 4 weeks of treatment, normal brain MRI at diagnosis, and normal cerebrospinal fluid or mild pleocytosis (< 20 WBC/ml). The NMDA receptor encephalitis 1-year functional status score (NEOS) assigns 1 point to each of these variables and strongly correlates with the probability of poor functional status at 1 year (08). As patients can have slow but continual improvement for up to 2 or more years, the NEOS score more closely aligns with the velocity of clinical improvement rather than final outcome.
Importantly, some patients considered to be fully recovered can have persistent, subtle cognitive and behavioral deficits (27). In a study of patients who were younger than 18 years of age at disease onset, one fifth still had behavioral deficits and difficulty at school or work after 5 or more years (09). This study also showed that the younger the patient was at disease onset, the more probable they were to have persistent long-term deficits.
Clinical vignette
A 21-year-old female in prior good health was brought to the emergency room by her family for an abrupt change in behavior described as bizarre and aggressive alternating with periods of calm and inattention. She had stopped eating and was sleeping poorly. In the emergency room she had moments of being appropriate but would suddenly become agitated. Medical and neurologic examinations were without focal findings, and she was afebrile. An unenhanced CT scan of the brain, electrocardiogram, toxicology screen, and general blood tests were normal. She was admitted to the psychiatric ward for further evaluation. Observations over several days noted disorganized thinking and auditory hallucinations consistent with psychosis. She was started on antipsychotic and sedative medications, but continued to worsen over 1 week. A day before institution of electroconvulsive therapy, she had a generalized seizure and was transferred to the ICU. Examination revealed decreased consciousness and orofacial dyskinesias. Routine CSF studies and MRI were normal. The EEG showed diffuse slowing. She was empirically given antiviral treatment. After 1 week, results of CSF testing revealed antibodies to the NMDA receptor, and she was started on high-dose corticosteroids and IVIg. Pelvic MRI was normal. Over 3 weeks, her seizures and level of consciousness improved, and she was discharged after 8 weeks. She recovered to baseline over 8 months.
Biological basis
Etiology and pathogenesis
In some patients, the trigger of the autoimmune response appears to be the systemic expression of NMDA receptors by an associated tumor (often ovarian teratoma).
The preceding viral prodrome reported by many patients may play a role in priming the immune system. Some patients have other autoimmune phenomena suggesting a predisposition to develop autoimmunity. About 20% of patients with herpes simplex viral encephalitis develop neurologic symptoms and anti-NMDA receptor antibodies after recovery from the viral illness (05; 04). It has been postulated that the destruction of brain tissue by the virus results in the release of neuronal antigens and subsequent development of autoimmunity. In many patients, the trigger remains unknown. In some patients, anti-NMDA receptor encephalitis occurs simultaneously or sequentially with clinical or imaging features of demyelinating disorders (46). This subset of patients often have immunity to myelin oligodendrocyte glycoprotein or AQP4 (03; 36). Whether there is a pathogenic relationship between these disorders is unclear.
Pathophysiology. Patients with anti-NMDA receptor encephalitis have antibodies that target the GluN1 subunit of the NMDA receptor.
Reactivity of anti-NMDA receptor antibodies in the CSF of a patient with anti-NMDA receptor encephalitis
Section of rat hippocampus immunostained with the CSF of a patient with anti-NMDA receptor encephalitis (A); boxed area shown in detail in (B). Immunostaining of live dissociated fetal rat hippocampal neurons demonstrates intense ...
Binding of the antibodies to the receptor results in disruption of cell-surface dynamics of NMDA receptors and antibody-mediated cross-linking and internalization of the receptors in both inhibitory and excitatory neurons and a reduction of NMDA receptor-mediated currents (41; 37). This alteration of NMDA receptor function results in the learning, memory, and other behavioral deficits observed in patients with the disorder and is similar to the symptoms seen with the use of NMDA receptor antagonists. The decrease of NMDA receptors is reversible on removal of the antibodies, which explains the ability of patients to recover. The antibodies are of the IgG class and are highly specific for anti-NMDA receptor encephalitis. Antibodies targeting other NMDA receptor subunits or of IgA or IgM class have been described in low titers in patients with a variety of immune and nonimmune conditions, as well as neurologically normal subjects, and are unrelated to this disease (28). A study including two series of patients found that between 4% and 7.5% of patients with anti-NMDA receptor encephalitis harbored concurrent antibodies against glial proteins such as MOG, AQP4, or GFAP or against other neuronal cell surface antigens, including the AMPA, GABA(A), and GABA(B) receptors (36). Except for GFAP, which did not associate with distinct clinical-radiological features, the presence of the other antibodies conferred additional clinical features including MRI findings not commonly seen in anti-NMDA receptor encephalitis, as well as unusual comorbidities and atypical tumor associations. Patients with concurrent neuronal antibodies had poorer outcomes compared to patients with only anti-NMDA receptor antibodies.
Epidemiology
The incidence and prevalence of NMDA receptor encephalitis are not described. Data suggest that it is the second most common cause of antibody-associated encephalitis after MOGAD and a more frequent cause of encephalitis than any single viral entity (22). A retrospective cohort study of a large healthcare database from Southern California found that NMDA receptor encephalitis more often affected Black, Asian/Pacific Islanders, and Hispanic persons compared to other ethnic groups (01). It is not clear how these data would extrapolate to other populations.
Prevention
No preventative strategies are known at this time.
Differential diagnosis
Confusing conditions
Patients presenting with acute changes in behavior or new-onset psychiatric manifestations may initially be diagnosed with a psychiatric disorder (acute psychosis or schizophrenia), drug abuse, or malingering. Diagnostic clues of anti-NMDA receptor encephalitis include the presence of severe sleep dysfunction (mainly insomnia at disease onset), disinhibition, agitation, fluctuating catatonia, absence of a history of psychiatric disease, and cognitive impairment, among others (12). Careful examination often reveals associated neurologic findings that may initially be subtle and should lead to further evaluation. New-onset seizures, encephalopathy, and CSF pleocytosis can suggest infectious encephalitis, but evaluations for an infectious agent are negative. If neuroleptics have been given, the development of rigidity, catatonia, and fever (possibly as a result of autonomic dysfunction) can suggest malignant neuroleptic syndrome (35). Repetitive stereotypic movement such as orofacial dyskinesias can be mistaken for seizures or status epilepticus that can be ruled out with video-EEG (18). Some cases of postpartum psychosis or those diagnosed as encephalitis lethargica have been shown to be cases of anti-NMDA receptor encephalitis (11; 19). During the postacute stage, the cognitive-psychiatric syndrome can resemble stabilized schizophrenia (27).
Diagnostic workup
Evaluation includes a detailed clinical history and medical and neurologic examinations, routine blood and CSF analyses, and MRI and EEG to rule out infectious, metabolic, or structural causes. In 80% of patients, the CSF will show lymphocytic pleocytosis, at times with increased proteins or oligoclonal bands. Testing for NMDA receptor antibodies should initially be done in CSF as 13% to 15% of cases can have negative serum studies (24; 26). Less than 50% of patients have MRI findings, usually transient increased signal in brain cortical or subcortical regions, cerebellar cortex, or, less frequently, brainstem. Less often, there is mild or transient meningeal or cortical enhancement. Almost 90% of patients have EEG abnormalities, including generalized slow or disorganized activity that may overlap with electrographic seizures (20). A unique EEG pattern called extreme delta brush is found in about 30% of cases (42). A search for an underlying tumor should be carried out, especially an ovarian teratoma in young women.
Extreme delta brush EEG pattern in anti-NMDA receptor encephalitis
EEG shows superimposed beta (arrows) frequency over delta waves (arrowheads) consistent with “extreme delta brush.” This pattern is very specific for anti-NMDA receptor encephalitis and associated with prolonged hospitalization. (...
Patients presenting with prominent psychiatric manifestations can be difficult to distinguish from those with a primary psychiatric disorder. A study found that patients with anti-NMDA receptor encephalitis and isolated psychiatric symptoms at disease onset have significantly higher levels of serum neurofilament light chain compared to individuals with first episode psychosis or healthy controls and, thus, may be a useful diagnostic marker (25).
Management
Drug treatment. Immunotherapy improves outcome and reduces relapses (39). Although there is no standard treatment protocol, most patients initially receive corticosteroids often combined with either IVIg or plasma exchange (47). In patients with no response to these treatments within approximately 2 weeks, rituximab or cyclophosphamide is usually initiated. Other therapies that have been reported include azathioprine, mycophenolate mofetil, methotrexate, bortezomib, and tocilizumab. Some series suggest that the use of rituximab improves outcome and reduces the risk of relapses; many practitioners incorporate rituximab in the initial treatment regimen, especially in patients with severe symptoms. Treatment is usually continued until the patient shows substantial clinical recovery. These treatments are well tolerated, even by patients in the ICU (plasma exchange should be avoided in patients with severe autonomic dysfunction or behavioral disturbances that could impact the safety of the procedure). No disease-specific toxicities have been reported. Routine evaluation of antibody titers is not recommended. Although CSF titers appear to correlate better with clinical course than serum titers, the antibodies remain elevated in many patients, even after successful treatment and clinical improvement (24). A few studies suggest that bortezomib may be a potentially useful drug when first- and second-line treatments fail. To date, the number of patients treated with bortezomib is small; most had been heavily treated with other immunotherapies (thereby impossible to rule out a delayed effect of previous treatments), and some received other drugs simultaneously (eg, methotrexate) (49). One study showed no benefit with bortezomib (43). Similar limitations apply to studies assessing the efficacy of tocilizumab, oral methotrexate, or intrathecal methotrexate (45; 34). An important problem in assessing the effects of these alternative treatments is the short time (approximately 4 weeks) used to define “treatment failure” after second-line therapies such as rituximab or cyclophosphamide. Therefore, future studies are needed to assess the efficacy of these drugs in the context of clinical trials. International consensus recommendations for the treatment of pediatric anti-NMDA receptor encephalitis support the use of corticosteroids for all patients with the addition of IVIg or plasma exchange in severe cases and rituximab for refractory disease (40).
Supportive care. Patients often require symptom management, including treatment for seizures, psychiatric disturbances, sleep disturbances, and movement disorders. Management of the severe neuropsychiatric symptoms is challenging, and there is evidence to suggest increased toxicity with neuroleptic medications (35). Some patients have received electroconvulsive therapy although there are insufficient data supporting its efficacy (50). Seizures, decreased level of consciousness, and autonomic dysfunction, including central hypoventilation, are frequent causes of admission to the ICU and are managed using standard protocols. A small number of patients (approximately 5%) develop episodes of severe bradycardia and cardiac pauses, requiring the use of a temporary pacemaker. Patients rarely develop chronic epilepsy and should be weaned from antiepileptics after recovery (17). Dyskinesias may improve with tetrabenazine (07); in case of severe orofacial dyskinesias with risk for self-injury (eg, of tongue, mouth), the use of focal botulinum toxin often improves some of the symptoms (51).
Surgery. If a tumor is identified early, removal is important to achieve a faster recovery (47).
Rehabilitation. Rehabilitation requirements vary depending on severity of illness and length of hospital stay, especially time in the ICU. Once patients are well enough to be discharged, or even when they appear to be back to baseline, they often have residual memory, behavior, and cognitive processing deficits that can lead to problems in social interactions and reintegration into normal activities, school, or work (27). These deficits usually improve over months and require a multidisciplinary team to address the specific deficits of each patient (27).
Outcomes
About 50% of patients respond to corticosteroids (methylprednisolone or equivalent) combined with IVIg or plasma exchange within 4 weeks of initiation (47). The remaining patients may show responses to rituximab or cyclophosphamide. Overall, 80% of patients will have substantial to full recovery that can take up to 2 years. About 12% of the patients have relapses within the first 2 years of the disease (47). Overall, about 20% of patients have relapses any time after the initial episode; relapses are often milder than the initial presentation and are responsive to treatment without cumulative disability (21). Relapses may be related to an occult or recurrent teratoma, but can occur in the absence of tumor. Although seizures are common in the acute phase of the disease, the majority of patients become seizure free and the risk of developing a chronic seizure disorder is low (44). Factors associated with good outcomes include the use of first-line treatment with plasma exchange alone, corticosteroids in combination with IVIg, or corticosteroids in combination with IVIg and plasma exchange, whereas lack of immunotherapy within 30 days of disease onset is associated with less probability of good outcome. Very young (< 2 years) and older age (> 65 years) are risk factors for poor outcome (39).
Special considerations
Pregnancy
There are a few case reports of anti-NMDA receptor encephalitis onset during pregnancy or the postpartum period, as well as some, but not definitive, evidence of placental transfer of the anti-NMDA receptor antibodies (30). One baby reported as having NMDA receptor antibody titers similar to the mother had cortical dysplasia, but the pregnancy was associated with uteroplacental insufficiency and additional problems, making it difficult to assess the pathogenic role of antibodies (30). Another baby developed transient neurologic symptoms that the authors postulated was due to transplacental transmission of antibodies (29). One newborn with hypotonia, hypoventilation, and abnormal movements had diffuse brain edema on MRI attributed to maternal-antibodies and died 3 weeks after birth (10). A retrospective study reported on 11 women, six who developed anti-NMDA receptor encephalitis during pregnancy and five who became pregnant while recovering from the encephalitis (32). There were no obstetrical complications but six of the babies were premature and one had transient respiratory distress. Nine of the infants with a median follow-up of 18 months had normal development. No adverse events have been reported when immunotherapy was given to mothers.
Anesthesia
Anesthetics such as ketamine, nitrous oxide, and xenon act as direct antagonists of the NMDA receptor. Although there is theoretical concern that their use in patients with NMDA receptor encephalitis should be avoided, they have been used safely in these patients.
Media
References
- 01
- Alsalek S, Schwarzmann KB, Budhathoki S, et al. Racial and ethnic disparities in the incidence of anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm 2024;11(4):e200255. PMID 38728608
- 02
- Ariño H, Muñoz-Lopetegi A, Martinez-Hernandez E, et al. Sleep disorders in anti-NMDAR encephalitis. Neurology 2020;95(6):e671-84. PMID 32576635
- 03
- Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020;19(3):234-46. PMID 32057303
- 04
- Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Neurological complications in herpes simplex encephalitis: clinical, immunological and genetic studies. Brain 2023;146(10):4306-19. PMID 37453099
- 05
- Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018;17(9):760-72.** PMID 30049614
- 06
- Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162(4):850-56. PMID 23164315
- 07
- Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord 2013;28(4):543-47. PMID 23400857
- 08
- Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 2019;92(3):e244-52. PMID 30578370
- 09
- Chen LW, Olivé-Cirera G, Fonseca E, et al. Very long-term functional outcomes and dependency in children with anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm 2024;11(3):e200235. PMID 38621190
- 10
- Chourasia N, Watkins MW, Lankford JE, Kass JS, Kamdar A. An infant born to a mother with anti-N-methyl-D-aspartate receptor encephalitis. Pediatr Neurol 2018;79:65-8. PMID 29310908
- 11
- Dale RC, Irani SR, Brilot F, et al. N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol 2009;66(5):704-09. PMID 19938173
- 12
- Dalmau J, Armangue T, Planaguma J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019;18(11):1045-57.** PMID 31326280
- 13
- Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7(12):1091-98. PMID 18851928
- 14
- Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378(9):840-51.** PMID 29490181
- 15
- Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63-74.** PMID 21163445
- 16
- Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61(1):25-36. PMID 17262855
- 17
- de Bruijn MAAM, von Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in ant-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 2019;92(19):e2185-96. PMID 30979857
- 18
- Dericioglu N, Vural A, Acar P, et al. Antiepileptic treatment for anti-NMDA receptor encephalitis: the need for video-EEG monitoring. Epileptic Disord 2013;15(2):166-70. PMID 23773862
- 19
- Doden T, Sekijima Y, Ikeda J, et al. Postpartum anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review. Intern Med 2017;56(3):357-62. PMID 28154283
- 20
- Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66(1):11-18. PMID 19670433
- 21
- Gabilondo I, Saiz A, Galan L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011;77(10):996-9. PMID 21865579
- 22
- Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54(7):899-904. PMID 22281844
- 23
- Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15(4):391-404.** PMID 26906964
- 24
- Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014;13(2):167-77. PMID 24360484
- 25
- Guasp M, Martín-Aguilar L, Sabater L, et al. Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis. Neurol 2022b;98(14):e1489-98. PMID 35145006
- 26
- Guasp M, Modena Y, Armangue, Dalmau J, Graus F. Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. Neurol Neuroimmunol Neuroinflamm 2020;7(2):e659. PMID 31900318
- 27
- Guasp M, Rosa-Justicia M, Muñoz-Lopetegi A, et al. Clinical characterization of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective observational cohort study and comparison with patients with schizophrenia spectrum disorders. Lancet Neurol 2022a;21:899-910. PMID 36115362
- 28
- Hara M, Martinez-Hernandez E, Ariño H, et al. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Neurology 2018;90(16):e1386-94. PMID 29549218
- 29
- Hilderink M, Titulaer MJ, Schreurs MW, Keizer K, Bunt JE. Transient anti-NMDAR encephalitis in a newborn infant due to transplacental transmission. Neurol Neuroimmunol Neuroinflamm 2015;2(4):e126. PMID 26140282
- 30
- Jagota P, Vincent A, Bhidayasiri R. Transplacental transfer of NMDA receptor antibodies in an infant with cortical dysplasia. Neurology 2014;82(18):1662-3. PMID 24706012
- 31
- Jones HF, Mohammad SS, Reed PW, et al. Anti-N-methly-d-aspartate receptor encephalitis in Maori and Pacific Island children in New Zealand. Dev Med Child Neurol 2017;59(7):719-24. PMID 28328164
- 32
- Joubert B, Garcia A, Planagumà J, et al. Pregnancy outcomes in anti-NMDA receptor encephalitis: case series. Neurol Neuroimmunol Neuroinflamm 2020;7(3):e668. PMID 31948997
- 33
- Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013;70(9):1133-9. PMID 23877059
- 34
- Lee WJ, Lee ST, Shin YW, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics 2020;18(1):474–87. PMID 32880854
- 35
- Lejuste F, Thomas L, Picard G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 2016;3(5):e280. PMID 27606355
- 36
- Martinez-Hernandez E, Guasp M, García-Serra A, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurol 2020;94(22):e2302-10. PMID 32161029
- 37
- Maudes E, Jamet Z, Marmolejo L, Dalmau J, Groc L. Positive allosteric modulation of NMDARs prevents the altered surface dynamics caused by patients’ antibodies. Neurol Neuroimmunol Neuroinflamm 2024;11(4):e200261. PMID 38771989
- 38
- Mueller SH, Farber A, Pruss H, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Ann Neurol 2018;83(4):863-9. PMID 29572931
- 39
- Nosadini M, Eyre M, Molteni E, et al. Use and safety of immunotherapeutic management of N-methyl-D-aspartate receptor antibody encephalitis. A meta-analysis. JAMA Neurol 2021a;78(11):1333-44. PMID 34542573
- 40
- Nosadini M, Thomas T, Eyre M, et al. International consensus recommendatons for the treatment of pediatric NMDAR antibody encephalitis. Neurol Neuroimmunol Neuroinflamm 2021b;8(5):e1052.** PMID 34301820
- 41
- Planaguma J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015;138(Pt 1):94-109.** PMID 25392198
- 42
- Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;79(11):1094-100. PMID 22933737
- 43
- Shin YW, Lee ST, Kim TJ, Jun JS, Chu K. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol 2018;5(5):598-605. PMID 29761122
- 44
- Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol 2017;30(3):345-53. PMID 28234800
- 45
- Tatencloux S, Chretien P, Rogemond V, Honnorat J, Tardieu M, Deiva K. Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol 2015;57(1):95-9. PMID 25040285
- 46
- Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75(3):411-28. PMID 24700511
- 47
- Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157-65.** PMID 23290630
- 48
- Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005;58(4):594-604. PMID 16178029
- 49
- Wang T, Wang B, Zeng Z, et al. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study. J Neuroimmunol 2021;354:577527. PMID 33652303
- 50
- Wright MA, Guasp M, Lachner C, et al. Electroconvulsive therapy in N-methyl-D-aspartate receptor encephalitis: A retrospective cohort and scoping review of the literature. J Neuroimmunol 2024;392:578369. PMID 38823118
- 51
- Zheng F, Ye X, Shi X, Poonit ND, Lin Z. Management of refractory orofacial dyskinesia caused by anti-N-methyl-d-aspartate receptor encephalitis using botulinum toxin. Front Neurol 2018;9:81. PMID 29520252
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Authors
-
Josep Dalmau MD PhD
Dr. Dalmau of IDIBAPS, University of Barcelona, receives royalties from Euroimmun for intellectual property rights and contracted research funds from Euroimmun as a principal investigator, has received consulting fees from Astellas Research Institute of America and Janssen Research & Development, and has received research funding from Sage Therapeutics.
See Profile -
Myrna R Rosenfeld MD PhD
Dr. Rosenfeld received royalties from Euroimmun and Athena Diagnostics for intellectual property rights.
See Profile
Editor
-
Francesc Graus MD PhD
Dr. Graus, Emeritus Professor, Laboratory Clinical and Experimental Neuroimmunology, Institut D’Investigacions Biomédiques August Pi I Sunyer, Hospital Clinic, Spain, has no relevant financial relationships to disclose.
See Profile
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- female>male
- Heredity
-
- none
- Population groups selectively affected
-
- A study of children in New Zealand demonstrated that those with Maori or Pacific Island ancestry had a higher incidence of NMDA receptor encephalitis compared to those without this ancestry, supporting a genetic predisposition (Jones et al 2017). However, a single-nucleotide polymorphism-wise analysis of a cohort of patients (largely young adults) found no genome-wide association of significance and only a weak association with major histocompatibility complex 1 B*07:02 (Mueller et al 2018).
- Occupation groups selectively affected
-
- none
ICD & OMIM codes
- ICD-10
-
- Other encephalitis and encephalomyelitis: G04.81
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuroimmunology
Multiple sclerosis: treatment of its symptoms
Oct. 30, 2024
-
Neuroimmunology
Anti-GQ1b antibody syndrome
Oct. 23, 2024
-
Neuro-Oncology
Paraneoplastic syndromes
Oct. 15, 2024
-
Neuroimmunology
Anti-IgLON5 disease
Oct. 10, 2024
-
Neuroimmunology
Balo concentric sclerosis
Oct. 04, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Neuroimmunology
Progressive encephalomyelitis with rigidity and myoclonus and glycine receptor antibodies
Oct. 03, 2024